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Summary
There is a lack of data regarding treatment and prognosis for the growing
group of oldest old patients with lymphoma. Therefore, we studied 2347
patients aged ≥85 years from the Danish and Swedish lymphoma registers
2000–2016 (Denmark) and 2007–2013 (Sweden). Outcome was assessed
using relative survival (RS). The 2-year RS overall for patients with aggres-
sive lymphomas was 38% [95% confidence interval (CI) 35–42%], of
whom 845 (66%) patients received active treatment (chemotherapy, radio-
therapy, immunotherapy, other). For aggressive lymphomas, not receiving
active treatment was associated with an inferior 2-year RS of 12% (95% CI
9–17%) compared to 49% (95% CI 45–53%) for patients who received
active treatment (excess mortality rate ratio 284, 95% CI 23–35;
P < 00001). For patients with indolent lymphoma, the 2-year RS was 77%
(95% CI 72–82%). Here, 383 (46%) patients received active treatment at
diagnosis, but did not have better 2-year RS (75%, 95% CI 67–81%)
compared to those who did not receive active treatment (83%, 95% CI 74–
89%). We conclude that outcomes for the oldest old patients with
lymphoma are encouraging for several subtypes and that active treatment is
associated with improved outcome amongst the oldest old patients with
aggressive lymphomas, indicating that age itself should not be a contraindi-
cation to treatment.
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Introduction
According to data from the United States Census Bureau the
world population aged >80 years has tripled from 1980 to
2010. This increase is projected to continue, particularly in
the oldest group aged >85 years.1 As the incidence of most
lymphoma subtypes increases with age, the population of old
patients with lymphoma is also expected to grow.2,3 Improve-
ments in cancer survival in recent decades have primarily
been achieved for the younger patient groups and popula-
tion-based studies have consistently reported worse outcomes
in older populations with cancer.2,4–6 This may be due to an
increased risk of treatment-related morbidity and mortality,
but also to suboptimal management of the oldest old patients
with cancer, due to fear of imposing undue toxicity.
Comorbidities, frailty, and old age per se largely preclude
inclusion of the very old in clinical trials.7 In the absence of
large randomised trials, the treatment of older patients is
informed mainly by single-arm trials and observational stud-
ies, and therefore optimal treatment strategies for old
patients remain poorly defined.3,8,9 Further, the management
of old patients with lymphoma is complicated by a greater
burden of comorbidity, physical/mental deconditioning and
a potential increase in treatment-associated complications
due to age-related differences in pharmacokinetics and
increased organ dysfunction.10,11
Lymphomas are generally highly chemosensitive and can
be cured even when occurring at advanced age, if managed
optimally.12,13 Moreover, with increased life expectancy and
better health amongst older persons, the general perception
of the oldest old as being too frail for curative therapy may
be outdated. With a rise in incidence and prevalence of lym-
phoma in an increasingly ageing population, more knowl-
edge regarding disease course, treatment and prognosis for
the oldest old patients with lymphoma is warranted. There-
fore, we aimed to characterise the population of very old
(aged ≥85 years) patients with lymphoma with regard to dis-
tribution of lymphoma subtypes and characteristics, treat-
ment patterns and relative survival (RS) using data from two
population-based national lymphoma registers.
Patients and Methods
Data sources and study population
This study was performed within the collaborative framework
of the Nordic Lymphoma Group, with participation of the
Swedish and Danish Lymphoma Groups and their popula-
tion-based registers. The Danish National Lymphoma Regis-
ter (LYFO) was initiated in 1982 and from 2000 coverage
was nationwide. In a recent validation study, LYFO demon-
strated a high degree of both completeness (95%) and cor-
rectness of entered variables with the Danish Cancer Register
and medical records used as reference.14,15 The Swedish Lym-
phoma Register (SLR) was established in 2000 and since
2007 includes detailed data regarding active treatment, treat-
ment type and response. Compared to the Swedish Cancer
Register, to which all cancer diagnoses are registered by law,
the coverage of the SLR is ~95% of all lymphoma cases diag-
nosed in Sweden.16
The study population included all patients aged ≥85 years
diagnosed with any type of lymphoma from 1 January 2000
to 31 December 2016 for Danish patients and from 1 January
2007 to 31 December 2013 for Swedish patients. Diagnoses
were made according to current World Health Organization
(WHO) classification pathology guidelines.17,18 Patients were
followed from diagnosis until death, emigration, or end of
follow-up (11 April 2015 for Swedish patients, 21 September
2019 for Danish patients), whichever occurred first. The
study was approved by the Regional Boards of the Ethics
Committees in Stockholm (2015/2028-31/2, 2019-01446) and
Southern Denmark (8/44586).
Patients were stratified according to aggressive and indo-
lent subtypes, as well as main lymphoma subtype according
to the WHO classification.19 Aggressive lymphomas encom-
passed diffuse large B-cell lymphoma (DLBCL), T-cell lym-
phomas (TCL; excluding primarily cutaneous variants),
Hodgkin lymphoma (HL), mantle cell lymphoma (MCL) and
other aggressive lymphomas [Burkitt lymphoma, primary
central nervous system lymphoma, primary mediastinal B-cell
lymphoma, aggressive lymphoma not otherwise specified
(NOS)]. Indolent lymphomas encompassed follicular lym-
phoma (FL), marginal zone lymphoma (MZL), lymphoplas-
macytic lymphoma (LPL) including Morbus Waldenstr€om,
and other indolent subtypes (hairy cell leukaemia, cutaneous
T-cell lymphoma and indolent lymphoma NOS). A propor-
tion of patients only had a recorded diagnosis of lymphoma
NOS and could not be further subclassified. The cohort was
linked to the Swedish and Danish Patient Registers 20,21 to
collect information on comorbid disease occurring 10 years
prior to lymphoma. Comorbidity was measured according to
the Charlson Comorbidity Index (CCI), as previously
described.22,23 Active treatment was defined as chemotherapy,
radiotherapy (RT), immunotherapy or other (surgery,
splenectomy, ultraviolet B/topical treatment or antibiotics).
No active treatment included management with watch-and-
wait and best supportive care including steroids only.
Statistical methods
Relative survival was used as a measure of net survival and
was estimated as the ratio of the observed all-cause survival
to the expected survival in an age-, sex-, country- and calen-
dar-period-matched population (assumed lymphoma free).
The Pohar Perme method was used to calculate expected sur-
vival in the matched Danish and Swedish general populations
using data obtained via the Human Mortality Database
(www.mortality.org). RS is a measure of total (both direct
and indirect) excess mortality associated with a lymphoma
diagnosis, with the advantage of not having to rely on
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classification of cause of death.24 Results are presented in
cumulative RS graphs and as 2-year RS estimates with 95%
confidence intervals (CIs). Additionally, we used multivari-
able flexible parametric models to estimate excess mortality
rate ratios (EMRRs). These models were fitted on the log
cumulative excess hazard scale and used restricted cubic
splines to model the baseline excess hazard function.25 All
models were fitted using five degrees-of-freedom for the
baseline excess hazard. Variables included in the multivari-
able model were age (assuming a linear effect), sex, CCI (cat-
egorised into scores of 0, 1 or ≥2), WHO Performance Status
(PS), Ann Arbor stage, country and active treatment. Propor-
tional hazards were assessed graphically through Martingale
residuals and tested formally using likelihood ratio tests for
interactions between the covariates and the spline represent-
ing the time scale. Time-varying effects were allowed for age,
WHO PS and country. Separate analyses were performed for
individual lymphoma subtypes and aggressive versus indolent
lymphomas. Statistical analyses were performed with STATA
software, version 15 (StataCorp., College Station, TX, USA).
Results
Patient characteristics and treatment
A total of 2347 consecutive patients aged ≥85 years with any
lymphoma subtype were identified during the study period.
Of these, 1159 were Danish and 1188 were Swedish, consti-
tuting 6% and 9% of all Danish and Swedish patients diag-
nosed with a lymphoma during the study period respectively.
Overall, 1283 (55%) had an aggressive lymphoma subtype,
835 (36%) an indolent subtype and 229 (10%) had a lym-
phoma NOS (Table I). DLBCL was the most commonly
occurring subtype (n = 924, 39%). Patients with a lymphoma
NOS diagnosis more often presented with a CCI of >1 and
were less likely to receive active treatment.
The median (range) age in the study population was
87 (85–105) years, with 579 (25%) patients aged ≥90 years.
Most patients were women, 1329 (57%). In the whole
cohort, 990 (42%) had a CCI of 0, 541 (23%) had CCI of 1
and 816 (35%) had a CCI of ≥2; with a similar distribution
amongst aggressive and indolent lymphoma subtypes
(Table II). Patient characteristics differed by country regard-
ing proportion of patients with comorbidity (a larger pro-
portion of Danish patients had no comorbidity, 48% vs
36%), but were otherwise similar (Table S1).
Treatment information was available for 2034 (87%)
patients, of whom 1319 (65%) received active treatment and
715 (35%) did not. Patient characteristics for the 313 (13%)
patients with missing treatment data were similar to those
who received no active treatment (data not shown).
Aggressive lymphomas
Among patients with aggressive lymphomas, 845 (66%)
received active treatment (Table III), most often chemother-
apy (n = 628, 74%). Patients who received active treatment
more often presented with WHO PS 0–1, Stage I–II, CCI 0
and age-adjusted International Prognostic Index (aaIPI) 0–1,
compared to those who did not receive active treatment
(Table II). The most commonly administered regimen was
CHOP (cyclophosphamide, doxorubicin, vincristine and
prednisone), and 340 (40%) patients started standard therapy
defined as either CHOP or CEOP (cyclophosphamide, epiru-
bicin, vincristine, prednisone; 76% with rituximab)
(Table S2). Among patients treated with rituximab-CHOP
(R-CHOP), 143 (43%) only completed one to three cycles.
RT was given to 231 (27%) patients, of whom 86 (10%)
received RT in combination with chemotherapy and 145
(17%) as monotherapy (Table S2).
The 2-year RS for patients with aggressive lymphoma
subtypes was 38% [95% confidence interval (CI) 35–42%].
For those who received active treatment, the 2-year RS was
49% (95% CI 45–53%) with a plateau of RS of 44% at
5 years. For those without active treatment, the 2-year RS
was 12% (95% CI 9–17%), with the highest excess mortal-
ity within the first 3 months (3-month RS: 24% for patients
who did not receive treatment; Fig 1A). Excess mortality in
a multivariable model was close to threefold increased
among patients who did not receive active treatment com-
pared to those who did (EMRRadj 284, 95% CI 23–35;
P < 00001). The RS rates for individual subtypes are pre-
sented in Fig 2. Especially for patients with DLBCL, active
treatment was associated with improved outcome [2-year
RS 51% (95% CI 46–56%) vs. 10% (95% CI 7–15%)]. Fur-
ther, with standard treatment (R-CHOP or R-CEOP,
n = 340) the 2-year RS was 64% (95% CI 60–73%) whereas
with low-intensive systemic therapies [cyclophosphamide,
oncovin, prednisone (COP) or single-agent chemotherapy],
RT or immunotherapy only, 2-year RS was 40% (95% CI
34–47%).
Table I. Distribution of lymphoma subtypes in 2347 patients aged
≥85 years at lymphoma diagnosis in Denmark and Sweden.
Lymphoma subtype N (%)
Aggressive subtypes All: 1283
Diffuse large B-cell lymphoma 924 (39)
T-cell lymphoma 103 (4)
Hodgkin lymphoma 65 (3)
Mantle cell lymphoma 138 (6)
Aggressive other 53 (2)
Indolent subtypes All: 835
Follicular lymphoma 201 (9)




Indolent other 244 (10)
Lymphoma not otherwise specified 229 (10)
Lymphoma Characteristics and Treatment Among the Oldest Old
ª 2020 The Authors. British Journal of Haematology published by British Society for
Haematology and John Wiley & Sons Ltd. British Journal of Haematology, 2021, 192, 551–559
553
Prognostic factors associated with inferior outcomes in a
multivariable analysis were age, female sex, WHO PS 2–4,
Stage III–IV disease, presence of B symptoms and CCI score
of >1 (Table S3). There were no significant differences by sex
in distribution of prognostic factors or treatment, except for
a lower proportion of female patients with aggressive lym-
phomas who started standard treatment (23%) compared to
male patients (30%) (data not shown). Outcomes were simi-
lar by calendar period (2000–2008 vs. 2009–2016, Fig-
ure S1a).
Indolent lymphomas
Among patients with indolent lymphomas, 46% received
active treatment. These patients more often had Stage I–II
disease and a lower aaIPI score, but otherwise baseline char-
acteristics were similar to those who did not receive active
treatment, including CCI score (Table II). For patients man-
aged with active treatment, 234 (61%) received
chemotherapy, most often chlorambucil (n = 155, 66%). In
all, 58 (15%) patients received RT as monotherapy
(Table III). The use of RT was most predominant among
lower stages, with 47% and 29% of patients with Stage I and
II receiving RT. The proportion of patients treated with
immunotherapy alone was 14% (Table S2).
The 2-year RS for patients with indolent lymphomas was
77% (95% CI 72–82%) overall, 83% (95% CI 74–89%) for
those who did not receive treatment and 75% (95% CI 67–
81%) for those who did (Fig 1B) (EMRRadj 068, 95% CI
04–11; P = 014). Administration of active treatment was
not associated with improved RS for any of the individual
indolent subtypes, and overall RS rates were encouraging for
all indolent subtypes (2-year RS >70%, RS for individual
subtypes are presented in Fig 2).
Prognostic factors associated with adverse outcomes in a
multivariable analysis were WHO PS 2–4 and presence of B
symptoms (Table S3). Outcome improved during the study
period, with a 2-year RS of 82% (95% CI 76–87%) for
Table II. Characteristics of lymphoma patients aged ≥85 years at diagnosis in Denmark and Sweden, overall and stratified by aggressive versus
indolent lymphoma subtype and active versus no treatment.
Characteristic Whole cohort
Aggressive subtypes* Indolent subtypes*
All patients Active treatment† No treatment† All patients
Active
treatment† No treatment†
N (%) 2347 (100) 1283 (61) 845 (66) 284 (22) 835 (39) 383 (46) 333 (40)
Age, years, median (range) 87 (85–105) 87 (85–105) 87 (85–101) 88 (85–105) 87 (85–100) 87 (85–100) 87 (85–99)
Sex, n (%)
Male 1018 (43) 560 (44) 374 (44) 110 (39) 378 (45) 167 (44) 160 (48)
Female 1329 (57) 723 (56) 471 (56) 174 (61) 457 (55) 216 (56) 173 (52)
WHO PS, n (%)
0–1 1535 (65) 740 (58) 580 (69) 93 (33) 655 (79) 307 (80) 252 (76)
2–4 742 (32) 505 (39) 253 (30) 175 (62) 155 (19) 68 (18) 71 (21)
Missing 70 (3) 38 (3) 12 (1) 16 (6) 25 (2) 8 (2) 10 (3)
Ann Arbor Stage, n (%)
I–II 697 (30) 462 (36) 359 (43) 67 (24) 185 (22) 100 (26) 63 (19)
III–IV 1275 (54) 612 (48) 407 (48) 132 (46) 538 (65) 247 (65) 225 (68)
Missing 375 (16) 209 (16) 79 (9) 85 (30) 112 (13) 36 (9) 45 (13)
aaIPI, n (%)
0 381 (16) 225 (18) 186 (22) 25 (9) 127 (15) 43 (13) 43 (13)
1 683 (29) 302 (23) 240 (28) 36 (13) 315 (38) 136 (41) 136 (41)
2 488 (21) 269 (21) 199 (24) 43 (15) 181 (22) 60 (18) 60 (18)
3 220 (9) 169 (13) 93 (11) 55 (19) 23 (3) 10 (3) 10 (3)
Missing 575 (25) 318 (25) 127 (15) 125 (44) 189 (22) 83 (25) 83 (25)
CCI score, n (%)
0 990 (42) 543 (42) 391 (46) 98 (35) 363 (43) 141 (42) 141 (42)
1 541 (23) 303 (24) 188 (22) 74 (26) 186 (22) 77 (23) 77 (23)
>1 816 (35) 437 (34) 266 (31) 112 (39) 286 (34) 115 (35) 115 (35)
Active treatment, n (%)
Yes 1319 (56) 845 (66) 383 (46)
No 715 (31) 284 (22) 333 (40)
Missing 313 (13) 154 (12) 119 (14)
aaIPI, age-adjusted International Prognostic Index; CCI, Charlson Comorbidity Index; WHO PS, World Health Organization Performance Status.
*Patients with a lymphoma NOS diagnosis not included in either subdivision.
†Patients with missing treatment data not included.
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554 ª 2020 The Authors. British Journal of Haematology published by British Society for
Haematology and John Wiley & Sons Ltd. British Journal of Haematology, 2021, 192, 551–559
patients diagnosed 2009–2016, compared to 66% (95% CI
57–74%) 2000–2008 (Figure S1b).
Discussion
We present real-world data on a large, consecutive cohort of
the oldest old patients (aged ≥85 years) with lymphoma, pro-
viding important information for both patients and treating
clinicians. We demonstrate that administration of active
treatment significantly reduced the excess mortality associ-
ated with aggressive lymphomas amongst the very old. This
indicates that age in itself should not be a contraindication
for treatment and that efforts to identify patients who will
benefit from treatment and increase treatment tolerability for
the oldest old patients with lymphoma are warranted. Fur-
ther, we demonstrate encouraging RS for indolent lym-
phomas overall, both among actively treated and other
patients.
For aggressive lymphomas, administration of active treat-
ment was associated with a 2-year RS of 49% and a 5-year
RS of 44%, demonstrating that intensive, curative treatment
is both feasible and tolerable for a proportion of the oldest
old patients with lymphoma. Active treatment was especially
beneficial for patients with DLBCL receiving standard treat-
ment with an encouraging 2-year RS of 64%. However, this
result needs to be interpreted with caution due to the inher-
ent risk of confounding by indication and the selection of fit
patients for standard intensive treatment. Data regarding
dose reductions were not available, but it is likely that the
majority of patients in the present study received attenuated
regimens. Non-completion of treatment was also common,
with 43% of patients receiving R-CHOP only completing one
to three cycles, although a proportion of these may be pre-
planned due to limited-stage disease. Nonetheless, it is evi-
dent that these reduced chemotherapy protocols have the
potential to achieve cure for a proportion of old patients.
Overall, our outcomes are comparable with those from
Peyrade et al.12 who found that the attenuated R-mini-
CHOP regimen may enable remission, cure and/or good pal-
liation without intolerable toxicity, and a few other
reports.26,27
The improved survival seen for patients with aggressive
lymphomas who received active treatment calls for better
tools to evaluate treatment eligibility in the oldest old, to
avoid diagnostic delay and to identify regimens with high
tolerability. Currently, there are no perfect methods to do
this as both the well-validated Complete Geriatric Assess-
ment (CGA) and Q8-questionnarie have the inherent risk
of interpreting lymphoma-associated symptoms as
frailty,3,7,28 although a prognostic score integrating the
CGA, IPI and haemoglobin value has demonstrated prog-
nostic significance.29 Further, more liberal use of RT and
supportive drugs, such as granulocyte-colony stimulating
factors, optimisation of general health and involvement of
family caregivers could potentially increase the number of
patients eligible for active treatment.3 Prior studies have
reported improved survival rates with pre-planned dose
reductions among patients aged ≥85 years.30,31 Also, pre-
phase treatment with steroids has been shown to improve
physical status and enable treatment of older patients.32
The field of novel targeted drugs is also very promising in
this context.28,33 Likewise, it is clear from our subtype-
specific RS results that older patients diagnosed with TCL,
other aggressive lymphomas, MCL and HL have a rela-
tively poor prognosis regardless of whether they receive
treatment or not, indicating a need for novel treatment
strategies.34,35
For indolent subtypes, active treatment was not associated
with a reduction in excess mortality. As not all indolent lym-
phomas require treatment this finding is plausible, as lym-
phomas selected for a watch-and-wait strategy are likely
associated with better prognosis. Also, the lack of association
between treatment and improved survival for patients with
indolent subtypes strengthens the notion that the primary




active treatment n = 1319
(56% of all patients)
Aggressive subtypes*
n = 845 (66% of all patients
with aggressive lymphoma)
Indolent subtypes†
n = 383 (46% of all patients
with indolent lymphomas)
Chemotherapy (RT) 921 (70)† 628 (74)† 234 (61)
Chemotherapy no RT 818 (62) 531 (63) 232 (61)
Chemotherapy + RT 92 (7) 86 (10) 2 (0)
RT only 221 (17) 145 (17) 58 (15)
Immunotherapy only 90 (7) 25 (3) 54 (14)
Other treatment only 19 (1) 10 (1) 8 (2)
Unknown treatment 68 (5) 37 (4) 29 (8)
RT, radiotherapy. Other treatment = surgery, splenectomy, ultraviolet B/topical treatment, antibiotics.
*Patients with lymphoma NOS diagnosis not included in either subdivision.
†11 patients with missing RT data.
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indication for treatment among older patients with indolent
lymphomas should be relief of symptoms. Only a few studies
have evaluated the outcome among very old patients with
indolent lymphomas and there is no consensus on standard
treatment.8,9,36 Thus, the encouraging RS rates for old
patients with indolent lymphoma demonstrated in our pre-
sent study provides important clinical information both for
clinicians who manage older patients with lymphoma and
for the patients and their relatives.
In our present study, the comorbid burden among
patients with indolent lymphoma did not differ by treatment,
and comorbidity did not impact excess mortality. In contrast,
among aggressive subtypes, patients who received active
treatment had less comorbidity. Interestingly, as previously
demonstrated by our group, comorbid patients with DLBCL
and male patients with MCL treated with curative intent did
not have inferior lymphoma-specific outcome compared to
non-comorbid patients with DLBCL and MCL.22,37 Hence,
(A)
(B)
Fig 1. Cumulative relative survival stratified by
active treatment (AT) yes/no for patients with
(A) aggressive and (B) indolent lymphoma
subtypes with number at risk presented below
the graph. [Colour figure can be viewed at wile
yonlinelibrary.com]
T. W€asterlid et al.
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the mere presence of comorbidity should not determine
treatment choice, although treatment may need to be
adapted in the presence of some comorbidities. Further, we
noticed that a large proportion of our patients did not have
any prior comorbidity, according to the CCI classification.
This may indicate that the very old lymphoma population,
particularly patients with asymptomatic indolent lymphomas,
constitutes a selected group of comparatively healthy older
patients, fit enough to undergo diagnostic evaluation.
Regarding the distribution of other clinical characteristics
they were similar in our present study to what has previously
been reported for older patients with lymphoma.8,38,39 This
also applies to prognostic factors, although for patients with
indolent lymphomas only the presence of B symptoms and
WHO PS score remained significant.
Distribution of lymphoma subtypes in the present study
was largely similar to that of the general lymphoma popula-
tion.40 However, there was a lower frequency of FL, MZL
and HL cases in our population, whereas patients with ‘lym-
phoma NOS’ were more numerous. This may also be indica-
tive of a lower diagnostic intensity, especially among
potentially asymptomatic indolent lymphomas, among the
very old.
In the present study, we provide valuable data regarding
clinical characteristics and prognosis of the largely unstudied,
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Fig 2. Cumulative relative survival (RS) stratified by individual subtypes and by active treatment yes/no, with RS rates listed below:Diffuse large
B-cell lymphoma (DLBCL): 2-year RS overall: 41% (95% CI 37–45%), for active treatment: 51% (95% CI 46–56%), for no treatment: 10% (95%
CI 7–15%).T-cell lymphoma (TCL): 2-year RS overall: 26% (95% CI 17–36%), for active treatment: 33% (95% CI 20–46%), for no treatment:
13% (95% CI 3–30%).Aggressive other: 2-year RS overall: 17% (95% CI 8–29%), for active treatment: 40% (95% CI 17–62%), for no treatment:
0% (95% CI 0–0%).Hodgkin lymphoma (HL): 2-year RS overall: 32% (95% CI 19–45%), for active treatment: 40% (95% CI 21–58%), for no
treatment: 22% (95% CI 6–43%).Mantle cell lymphoma (MCL): 2-year RS overall: 41% (95% CI 31–51%), for active treatment: 52% (95% CI
38–64%), for no treatment: 25% (95% CI 11–40%).Follicular lymphoma (FL): 2-year RS overall: 68% (95% CI 58–77%), for active treatment:
65% (95% CI 51–76%), for no treatment: 61% (95% CI 59–93%).Marginal zone lymphoma (MZL): 2-year RS overall: 86% (95% CI 72–93%),
for active treatment: 92% (95% CI 64–98%), for no treatment: 78% (95% CI 52–91%).Morbus Waldenstr€om (Mb Waldenstr€om): 2-year RS over-
all: 87% (95% CI 76–93%), for active treatment: 81% (95% CI 62–91%), for no treatment: 90% (95% CI 69–97%).Indolent other: 2-year RS
overall: 71% (95% CI 61–78%), for active treatment: 63% (95% CI 48–76%), for no treatment: 77% (95% CI 61–87%). [Colour figure can be
viewed at wileyonlinelibrary.com]
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≥85 years in Denmark and Sweden. The use of population-
based data provides a unique cohort capturing >95% of all
lymphoma cases. Our present report of RS also represents a
strength, as mortality due to other causes is prevalent in this
age group. The high mortality in this age group inevitably
also limits the number of patients left in later years of fol-
low-up, despite the relatively large study population at diag-
nosis. Thus, the RS for later time period after diagnosis
needs to be interpreted with caution due to small numbers.
Other limitations include the lack of data regarding toxicity
and frailty assessment. Although the use of relative survival
captures excess mortality caused both directly and indirectly
by the cancer through for example intolerable toxicity of
treatment, the lack of toxicity data, dose reductions, and
other patient-level data preclude us from further deducing
associations between patient characteristics, treatment admin-
istration and tolerability.
To conclude, we demonstrate encouraging RS rates for
very old patients diagnosed with lymphoma, for several sub-
types, and show that active treatment improves RS for old
patients with aggressive lymphomas, DLBCL in particular.
Thus, age itself should not constitute a contraindication to
treatment. For patients with indolent lymphomas, treatment
was not associated with reduced excess mortality, wherefore
treatment for indolent subtypes should probably be reserved
for symptomatic patients. Prospective studies to determine
relevant factors to identify patients who will tolerate and
benefit from treatment among the oldest old patients with
lymphoma are warranted.
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